That narrative generates the course of my own “Do Ask Do Tell” books. Jack’s level of detail is comparable to mine in the first chapter of my first DADT book (1997), on Amazon. My narrative tends to be a little more abstract.
Jack is still a senior in high school, and one wonders how he can get all his homework done ("senioritis"). He is set to enter Stanford in the fall of 2015. (A good chance to meet Mark Zuckerberg.) He travels constantly, and even indicated in a tweet that a hotel gave him a "free fish" to take care of in a bowl in the room.
See also the "Andraka" label on my "Major Issues" blog (Jan. 28. Feb. 27, 2015).
Update: March 26, 2015
Not to throw cold water on Jack's accomplishment, but a piece in "Scholarly Kitchen" by Kent Anderson takes him to task here (with the "Jack in the Beanstalk" analogy from "Into the Woods"). Note it is dated early Jan. 2014, before Andraka's 17th birthday. The issue (as explored in many detailed comments) is the lack of a peer-reviewed published article on the test, before Andraka set up an LLC and filed a patent application. Some observers (in the comments) see a contradiction between Andraka's embracement of Open Access (via Aaron Swartz) and his own lack of publication. Of course, a peer review article takes a long time to get published. And his $75000 prize was for a science fair competition, not a royalty from the pharmacy business. Still, it would seem that the test would have to undergo rigorous testing at various labs (hopefully including NIH-NCI in Bethesda) before it can claim commercial value. The real importance of the innovation is that the concept could be used in many quick diagnostic tests based on specific proteins and antibodies. And, in his case, any final paper should be "free" to the public, given the issue. (I have to chuckle at the title of the publication: Remember "The Thirsty Scholar' in the movie "The Social Network"?)
Nick Bryant throws some cold water on Jack's work in an Australian paper March 29, 2015 here (Andraka visited Australia in August before starting at Stanford).
Jack is on tour around the country now, visiting schools. How does someone keep up with schoolwork while traveling? He even got an "it's free" goldfish to feed in a hotel room (in Houston, I think).
Update: April 21, 2015
NBC News reports on a liquid biopsy test to detect return of cancer after chemotherapy, for certain tumors, link here. I don't know if it is similar in principle to Jack's test.
There is also a story from the University of Kansas (medical school is in Kansas City) on detecting tumor-associated molecules, perhaps related, here. That's where I went to graduate school myself in the 1960s (MA in Mathematics).
Update: Nov. 12, 2015
I found a story "Mesothelin: An early detection biomarker for cancer", in Pharmaceutical Intelligence, authored by Tilda Barluiya, April 21, 2013 here. At my own physical today, my own physician said that the test would have to be approved by the FDA and licensed before trials on early treatment of pancreatic cancer based on positive tests would commence. The test may be useful for a limited list of other cancers. But the concept to test for other marker proteins for other tumors is likely to attract other researchers and companies. I believe Stanford is helping Jack continue the experiments as he enters there as a freshman.
Update: Dec 18, 2016
My own physician said on my physical this year that he was surprised the test wasn't available yet. But I think it takes several years for a test like this to get into regular use, even if the patent is approved. I know of an eye surgeon who has gotten FDA approval for his laser surgery to remove floaters (here in VA) but his machine isn't in general use yet.
Update: June 6, 2018
Here is another detailed blog post on Jack's book that Google offers.